Recently, we demonstrated that predicted loss of function TET2 mutations (somatic and germline) are likely a novel cause of PAH (Potus et al. 2020), a finding confirmed by others (Hiraide et al. 2022). This evidence concerns the gene TET2 and pulmonary arterial hypertension.